Year Founded
2005
Ownership
Private
Employees
~249
Therapeutic Areas
HematologyDermatologyInfectious DiseasesRheumatology
Stage
Phase 1
Modalities
Protein therapeuticsOtherProtein therapeuticsProtein therapeuticsmRNA vaccineOther

BMIKorea General Information

Lead program BRE-AD01 for atopic dermatitis in Phase 1 trials in the US. Has commercialized BREXTEM-S for skin rejuvenation and BREXTEM-H for hair restoration.

Contact Information

Website
Primary Industry
[ "CDMO", "Biotech", "Medical Devices", "Pharma" ]
Corporate Office

Drug Pipeline

BxC-I17e
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to BMIKorea's pipeline data

Book a demo

Key Partnerships

Brexogen

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

BMIKorea Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view BMIKorea's complete valuation and funding history, request access »